High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma

Biol Blood Marrow Transplant. 2013 Jun;19(6):991-4. doi: 10.1016/j.bbmt.2013.03.008. Epub 2013 Mar 16.

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation*
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / immunology
  • Hodgkin Disease / mortality
  • Hodgkin Disease / pathology
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Survival Analysis
  • Transplantation, Autologous

Substances

  • Antineoplastic Agents